


How Adequan® Canine Works

Restore. Relieve. Renew.
Nothing works like Adequan® Canine.

As the only FDA-approved disease-modifying osteoarthritis drug (DMOAD), Adequan® Canine (polysulfated glycosaminoglycan) has a mode of action that empowers you to proactively treat the disease, not just the clinical signs.¹

How Adequan® Canine Works^{1,2} (polysulfated glycosaminoglycan)

The specific mechanism of action of Adequan® in canine joints is not known.¹



1. Adequan® Canine Package Insert, Rev 1/19.

2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997.

Here's how it may help:

Binds to components of the cartilage matrix to help prevent further degradation of the joints.

- Reduces inflammation and decreases pain.
- Inhibits release of degradative enzymes and inflammatory mediators to help restore balance.
- Stimulates the activity of existing cartilage components and improves synovial fluid to help renew joint mobility.

Discover if Adequan® Canine is the right choice.

03:16 |

[▶ Video Transcript](#)

The combination of disease treatment and supportive modalities can help slow progression of osteoarthritis (OA) and help promote mobility.



*All products have the potential for adverse events that should be considered in overall management of any disease.

Discover if Adequan® Canine is the right choice.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Help slow down the OA clock with a comprehensive plan.

Develop a personalized multi-modal plan that is specific to each patient that can include disease treatment, pain management, exercise, weight control and physical therapy.

[DIAGNOSING OA](#)

[▶ Video Transcript](#)

"The optimal management of OA focuses on strategies that slow down the clock."

Denis J. Marcellin-Little,
DEDV, DACVS, DECVS, DACVSMR

Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see [Full Prescribing Information](#).

1. Adequan® Canine Package Insert, Rev 1/19.

Let's stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL

DOG OWNER

CONTACT INFORMATION

[Contact Us](#)
[Adverse Event Reporting](#)
[Product Quality Complaints](#)
[Sign Up](#)
[Press Room](#)

ABOUT ADEQUAN® CANINE

[Dosing & Administration](#)
[Prescribing Information](#)
[Safety Information](#)
[Ordering Information](#)

AMERICAN REGENT ANIMAL HEALTH

[About Us](#)
[Our Brands](#)